OI
SRPT icon

Oakbrook Investments’s Sarepta Therapeutics SRPT Stock Holding History

Oakbrook Investments’s Portfolio SRPT Stock Details SRPT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q2 		– Sell
-1,775
Closed -$212K – 650
2019
Q1 		$212K Buy
+1,775
New +$228K 0.01% 575
2018
Q4 		– Sell
-1,975
Closed -$319K – 651
2018
Q3 		$319K Buy
+1,975
New +$270K 0.02% 534

Other funds holding SRPT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Oakbrook Investments's SRPT Position: Q2 2019 in Review

Oakbrook Investments sold out of Sarepta Therapeutics (SRPT) in Q2 2019, closing a stake of 1,775 shares — an estimated $212K sold.

Oakbrook Investments first reported a position in SRPT in Q3 2018 and held it in 2 quarters. The position peaked at $319K in Q3 2018. 365 funds tracked by Wall St. Rank hold SRPT as of Q2 2019.

  • Oakbrook Investments reported no remaining Sarepta Therapeutics position as of Q2 2019 after selling out during the quarter.
  • Oakbrook Investments sold 1,775 Sarepta Therapeutics shares in Q2 2019, an estimated $212K.
  • Oakbrook Investments first reported a position in Sarepta Therapeutics in Q3 2018 and held it in 2 quarters.
  • Oakbrook Investments's Sarepta Therapeutics position peaked at $319K in Q3 2018.
  • 365 funds tracked by Wall St. Rank held Sarepta Therapeutics as of Q2 2019.

Based on Oakbrook Investments's 13F filing for Q2 2019, filed 18 Jul 2019.